Beyond Air Inc. released its financial results for the fiscal year ending March 31, 2025. The company reported a significant increase in revenue, reaching $3.7 million compared to $1.2 million for the previous year. However, the company also reported a net loss of $48.5 million, slightly improved from the $64.3 million loss in the prior year. Operating expenses were reduced to $42.9 million from $61.7 million, driven by lower research and development and selling, general, and administrative costs. The company, a commercial-stage medical device and biopharmaceutical entity, continues to face challenges reflected in its comprehensive loss, which stood at $46.7 million, compared to $60.3 million in the previous year. No specific outlook or guidance was provided in the report.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。